REG - BSF Enterprise PLC - 3D Bio-Tissues Signs Supply Agreement with SeaWith

BSF EnterpriseAnnouncement

16/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251216:nRSP6710La&default-theme=true

RNS Number : 6710L  BSF Enterprise PLC  16 December 2025

16 December 2025

 

BSF Enterprise PLC

("BSF" or the "Company")

 

 

3D Bio-Tissues Limited Signs Commercial Supply Agreement with SeaWith

 

BSF Enterprise PLC (LSE:BSFA) (the "Company"), a leading innovator in
tissue-engineered materials, is pleased to announce that its subsidiary
company 3D Bio-Tissues (3DBT) has signed a Head of Terms with SeaWith, a
pioneering South Korean cultivated-meat company.

 

The agreement will see 3DBT deliver commercial supplies of City-Mix®, the
company's premium macromolecular crowder for cell culture, to SeaWith to help
reduce the cost and scale production of its cultivated beef product.
Founded in 2019, SeaWith is a South Korean biotechnology innovator employing
seaweed-derived technologies to produce sustainable, slaughter-free meat
alternatives. The company has raised over $8 million in venture funding to
date. Its flagship product line, Welldone™, focuses on cultivated beef and
other meat alternatives designed for scalability and environmental impact
reduction.

 

The value of the agreement to 3DBT is around £300K. Under the agreement,
SeaWith will be sent a regular supply of City-Mix to support its
cultivated-meat production pipeline, representing a key milestone in expanding
the product's reach into the cultivated-protein market. City-Mix® is
designed to improve cell density, growth efficiency, and tissue quality, while
significantly lowering production costs by reducing the amount of expensive
growth media required for SeaWith by around 30 per cent.

 

The global cultivated meat sector is gaining momentum, and South Korea is
emerging as one of Asia's most promising markets, supported by
government-backed initiatives such as the Regulatory-Free Special Zone (RFSZ).
This zone allows companies like SeaWith to bypass certain red-tape regulatory
hurdles for five years, enabling faster commercialisation of cultivated meat
products. The RFSZ is part of a broader national strategy to make South Korea
a global hub for food-tech, creating an environment for scaling production and
achieving price parity with conventional meat.

 

The country's alternative protein market is projected to grow at over 50% CAGR
by 2030, driven by food security concerns, environmental sustainability, and
rising demand for cultivated meat production. Overall, 90% of South Koreans
are willing to try cultivated meat, but price and taste remain key drivers.
Government investment and regulatory flexibility are expected to help overcome
these barriers, making South Korea one of Asia's most promising markets for
cultivated protein.

 

Che Connon, CEO of 3D Bio-Tissues, said: "This agreement marks a significant
milestone for 3D Bio-Tissues as we expand City-Mix® into one of Asia's most
dynamic cultivated meat markets. By partnering with SeaWith, a recognised
innovator in sustainable protein, we are demonstrating how our technology can
deliver real commercial impact, boosting cell yield, improving tissue quality,
and crucially lowering production costs to help make cultivated meat
economically viable at scale. We see this collaboration as a strong validation
of City-Mix® and an important step toward accelerating global adoption of
cultivated meat."

 

Heejae Lee, CTO and Co-founder of SeaWith said: "As Korea's designated
Regulatory Free Zone operator for cultivated meat, we are pleased to partner
with an industry leader like 3D Bio-Tissues as we move toward regulatory
approval. City-Mix® technology aligns exceptionally well with our
high-performing Hanwoo-derived muscle stem cells, supporting both robustness
and scalability in our production process. This collaboration represents a
meaningful step forward as we advance toward commercialisation."

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 

END

 

 

For more information and the chance to have your questions directly answered
by the management team, please head to our interactive investor hub via:
https://bsfenterprise.com/link/yOOKXy
(https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fbsfenterprise.com%2Flink%2FyOOKXy&data=05%7C02%7CGeorge.Esmond%40secnewgate.co.uk%7Cd8599c6327a24ed4dcd808de3bd5c3ea%7Ceae0b4d670d04d12a2336addd6e076a0%7C0%7C0%7C639013986457683688%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=s8HvXNOtuVfOaFjK8D8RWGYlMH1PdW4RAVq%2BVmSSD7Y%3D&reserved=0)

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com) or contact:

 

 BSF Enterprise PLC                 https://bsfenterprise.com/s/a1f22b (https://bsfenterprise.com/s/a1f22b)

 Geoff Baker - Executive Director

 Che Connon - CEO & Director

 Shard Capital (Broker)

 Damon Heath                        0207 186 9000

 Isabella Pierre                    0207 186 9927
 ISIN of the Ordinary Shares

 is GB00BHNBDQ51.

 SEDOL Code is BHNBDQ5.

 

Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43
(https://bsfenterprise.com/s/bb9f43)

 

About BSF Enterprise PLC

BSF Enterprise PLC (BSF) develops and commercialises cutting-edge
tissue-engineered solutions, including lab-grown leather, cultivated meat, and
corneal repair technologies. By leveraging its proprietary scaffold-free
platform, BSF aims to deliver sustainable alternatives to traditional
materials and meet global demand for environmentally responsible innovations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPGRCPUPAPWA



            Copyright 2019 Regulatory News Service, all rights reserved